The general theme of med-tech earnings through this cycle
seems to be that the market has gotten a little bit ahead of many of
the companies, leading to earnings reports that the sell-side
characterizes as "slightly disappointing." Among those is Becton Dickinson (NYSE: BDX )
, a generally reliable company that is structured more for long-term
performance than short-term growth. Analysts seem focused on the weak
results in diagnostics, but the overall picture hasn't really changed
all that much.
Follow this link for the full article:
Is Becton, Dickinson and Company a Buy?
No comments:
Post a Comment